Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion is a healthcare technology company with a positive outlook as it gains traction in the market for its Nociscan product, which provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. With commercial agreements, increased marketing efforts, and an expanding share count, the company is investing in sales, R&D, and IR to drive future growth. While risks exist, such as slower enrollment in clinical trials, the company's strong cash position and potential market opportunity make it a promising investment with a 12-month price target of $7.50.

Bears say

Aclarion is facing challenges with its CLARITY trial, with initial data analysis and disclosure of early interim results delayed until Q4 2026. Additionally, while the company has a healthy cash runway, they also authorized a share-repurchase program, suggesting potential concerns about their current positioning and valuation. The delay in trial data and mixed signals about financial confidence could indicate underlying issues with the effectiveness and potential market success of Nociscan.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Sep 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.